Stockscreener 앱 받기
38.09
1.20%
0.45
전일 마감가:
$37.64
열려 있는:
$37.45
하루 거래량:
575.37K
Relative Volume:
0.73
시가총액:
$3.28B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-5.8872
EPS:
-6.47
순현금흐름:
$-439.53M
1주 성능:
+6.72%
1개월 성능:
-1.55%
6개월 성능:
-29.23%
1년 성능:
-13.14%
1일 변동 폭
$36.92
$38.15
1주일 범위
$34.63
$38.15
52주 변동 폭
$29.59
$60.37
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
RARE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
38.09 | 3.28B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Nasdaq
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | RARE Stock News - GuruFocus
Ultragenyx Expands Team with 21 New Hires, Grants Nearly 37,000 Restricted Stock Units - Stock Titan
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BofA Adjusts Price Target for Ultragenyx (RARE) Ahead of Q1 Earnings | RARE Stock News - GuruFocus
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children | Libero Quotidiano.it - Libero Quotidiano
Mucopolysaccharidosis (MPS) Treatment Market Generated - openPR.com
How did Emil Kakkis build Ultragenyx into an ultrarare-disease powerhouse? - The Business Journals
BofA Adjusts Price Target on Ultragenyx Pharmaceutical to $80 From $83, Keeps Buy Rating - marketscreener.com
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline (NASDAQ:RARE) - Seeking Alpha
Roche's castoff Angelman drug gets second life in Oak Hill deal - FirstWord Pharma
Ultragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - MSN
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? - Yahoo Finance
X-linked Hypophosphatemia Market Future Business - openPR.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Is Carrying A Fair Bit Of Debt - simplywall.st
Ultragenyx stock hits 52-week low at $33.37 amid market challenges - Investing.com Canada
Ultragenyx stock hits 52-week low at $33.37 amid market challenges By Investing.com - Investing.com South Africa
How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week LowShould You Sell? - MarketBeat
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning - Benzinga
Ultragenyx price target raised to $117 from $104 at JPMorgan - TipRanks
Ultragenyx stock hits 52-week low at $36.99 amid market challenges - Investing.com Australia
Ultragenyx stock hits 52-week low at $36.99 amid market challenges By Investing.com - Investing.com South Africa
Strategic Move: Ultragenyx CCO Erik Harris to Drive Rezolute's Rare Disease Commercialization - Stock Titan
Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’ - insights.citeline.com
Can UX111 Script History As The First FDA-Approved Treatment For Sanfilippo Syndrome Type A? - RTTNews
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Ultragenyx Strengthens Team with Strategic RSU Grants Worth Millions - StockTitan
Ultragenyx price target lowered to $115 from $140 at Piper Sandler - Yahoo Finance
Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight By Investing.com - Investing.com Canada
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews - Benzinga
Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight - Investing.com
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace
Trending Report on X-linked Hypophosphatemia Market 2025-2032 - openPR
Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently? - Simply Wall St
Ultragenyx pharmaceutical CFO sells $72,114 in common stock By Investing.com - Investing.com Canada
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):